15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Maravai Lifesciences Holdings Inc, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $6.50 to $6.50, so the covering firms are broadly aligned. The average target of $6.50 sits 10% below the current $7.20. The rating mix has stayed broadly stable, with Buy-side ratings easing from 3 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.08 next quarter toward $-0.10 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Strong Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Maravai Lifesciences Holdings Inc.
As of Sep, 1 of 1 firms rate MRVI a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
MRVI EPS & revenue forecast
EPS · NEXT QUARTER
$-0.08
Range $-0.35 – $-0.03 · 7 analysts · +109% YoY
Next period, 7 analysts expect Maravai Lifesciences Holdings Inc to earn $-0.08 a share (range $-0.35 – $-0.03), versus $-0.04 a year earlier. Full-year consensus is $-0.18, growing to $-0.10 the year after.
REVENUE · NEXT QUARTER
$50.7M
Range $47.2M – $52.5M · 7 analysts · +2% YoY
Revenue is expected to reach $50.7M (range $47.2M – $52.5M), +1.6% year-over-year. Full-year consensus is $211.6M, rising to $225.7M next year.
Top analysts covering Maravai Lifesciences Holdings Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MRVI.
#1
Conor McNamara
RBC Capital · Rank #201
Buy
$5.00-30.6% to target
Overall win rate
34%
+ Follow
#2
Christian Schwab
Craig-Hallum · Rank #269
Buy
$5.00-30.6% to target
Overall win rate
41%
+ Follow
#3
Matthew Sykes
Goldman Sachs · Rank #274
Sell
$4.25-41.0% to target
Overall win rate
38%
+ Follow
#4
Brandon Couillard
Wells Fargo
Buy
$5.50-23.6% to target
Coverage
—
+ Follow
#5
CS
Catherine Schulte
Baird
Hold
$2.00-72.2% to target
Coverage
—
+ Follow
MRVI stock forecast FAQ
What is MRVI's average 12-month price target?+
The 1 analysts with a live target average $6.50 for Maravai Lifesciences Holdings Inc over the next 12 months, ranging from a $6.50 high to a $6.50 low.
Is MRVI stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover MRVI?+
1 analysts have an active rating on Maravai Lifesciences Holdings Inc, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering MRVI?+
Among analysts who currently cover MRVI, Conor McNamara of RBC Capital has the strongest overall Quantellect track record (Rank #201). Their current call is Buy with a $5.00 target.
What is Maravai Lifesciences Holdings Inc's projected EPS for next quarter?+
The consensus estimate is $-0.08 per share (range $-0.35 – $-0.03) across 7 analysts. Full-year EPS is projected at $-0.18, rising to $-0.10 the following year.
How much revenue is Maravai Lifesciences Holdings Inc expected to report next quarter?+
Consensus revenue is $50.7M (range $47.2M – $52.5M). Full-year revenue is projected at $211.6M, growing to $225.7M next year.
Have analysts been upgrading or downgrading MRVI lately?+
As of Sep, 1 of 1 firms rate MRVI a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MRVI calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
Wells Fargo
